Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 4/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | GLI1 | P08151 | 1/20 | 0.47 |
| ▸ | GLI2 | P10070 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774246 | 0.88 | FDFT1 (0.61) | FDFT1FFAR1GLI1GLI2AKR1C3 | |
| SCHEMBL23120183 | 0.81 | FDFT1 (0.57) | FDFT1FFAR1GLI1GLI2AKR1C3 | |
| SCHEMBL10106169 | 0.80 | MTNR1A (0.68) | FDFT1MTNR1AMTNR1BAKR1C3EPHX2 | |
| SCHEMBL23120147 | 0.80 | FDFT1 (0.58) | FDFT1GLI1GLI2AKR1C3PLAAT3 | |
| SCHEMBL2772929 | 0.79 | FDFT1 (0.66) | FDFT1FFAR1GLI1GLI2AKR1C3 | |
| SCHEMBL5354570 | 0.79 | FDFT1 (0.57) | FDFT1GLI1GLI2AKR1C3PLAAT3 | |
| SCHEMBL4520042 | 0.78 | EPHX2 (0.57) | HTTKMT2AEPHX2 | |
| SCHEMBL8351647 | 0.76 | FFAR1 (0.60) | FDFT1FFAR1HTT | |
| SCHEMBL17040294 | 0.76 | GLI1 (0.64) | FDFT1GLI1GLI2AKR1C3KMT2A | |
| SCHEMBL9781817 | 0.76 | FDFT1 (0.59) | FDFT1FFAR1GLI1GLI2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590321-B1 | ARYL ALKYL CARBAMATE DERIVATIVES PRODUCTION AND USE THEREOF IN THERAPY | SANOFI AVENTIS (FR) | 2010-04-28 | — | — | EP | disclosed |
| US-7632850-B2 | 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS | SANOFI-AVENTIS (FR) | 2009-12-15 | — | — | US | disclosed |
| US-7632850-B2 | 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS | SANOFI-AVENTIS (FR) | 2009-12-15 | — | — | US | disclosed |
| US-7632850-B2 | 2-amino-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate and 2-(methylamino)-2-oxoethyl 1-(4'-fluoro-1,1'-biphenyl-4-yl)cyclopropylmethylcarbamate; fatty acid amide (FAAH) hyrdrolase inhibitors; analgesics; neuropathic pain;psychological disorders; anticarcinogenic agents; AIDS | SANOFI-AVENTIS (FR) | 2009-12-15 | — | — | US | disclosed |
| US-20060014830-A1 | Arylalkylcarbamate derivatives production and use thereof in therapy | SANOFI-AVENTIS (FR) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014830-A1 | Arylalkylcarbamate derivatives production and use thereof in therapy | CBR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C5 | FDFT1 837/4885FFAR1 1023/4885GLI1 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.